CamStent Limited, a Cambridge, UK-based medtech company, has closed a £350,000 seed funding round.
Backers include LBA’s angel investors, which made the investment through the 2011 LBA EIS RoundTable Syndicate Fund.
Led by CEO Dave Hampton, CamStent is developing patented polymer coatings that resist the growth of bacteria on medical implants and devices. Its first commercial product is a compound that prevents catheter-acquired urinary tract infections.
The company intends to use the funding to develop its first catheter application as well as secondary applications for their biofilm-resistant coatings.